No information is available for this page. · Learn why
People also search for
May 11, 2024 · Acute Coronary Syndrome (ACS). Janssen. LIBREXIA- Actively Enrolling. Title- A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to ...
May 14, 2024 · It has only been assessed in a small phase II randomised, double-blind trial ... Standard treatment following acute coronary syndromes (ACS) ... LIBREXIA-STROKE ( ...
8 days ago · These trials are essential for validating the potential of FXI inhibitors to balance bleeding risk reduction and maintain anticoagulant efficacy. This review ...
May 4, 2024 · • Data from phase 2 trial of FXI/XIa inhibitors suggest low rates of bleeding. • Phase 3 trials are underway to evaluate efficacy in patients at risk of.
May 21, 2024 · Badanie Milvexian u uczestników po niedawnym ostrym zespole wieńcowym (LIBREXIA-ACS) ... Dyrektor Studium: Janssen Research & Development, LLC Clinical Trial, ...